title: Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum).
abstract: OBJECTIVE
  To evaluate risk factors for recurrent events in patients enrolled in the SteFlux (Superficial Thromboembolism Fluxum) clinical trial which compared different doses and duration of low molecular weight heparin (parnaparin) for superficial vein thrombosis (SVT).
  
  
  METHODS
  Outpatients with acute SVT of at least 4 cm in length of the internal or external saphenous veins or their collaterals were randomized in a double blind fashion to receive either parnaparin 8500 UI aXa od for ten days followed by placebo for 20 days or 8500 UI aXa od for ten days followed by 6400 UI aXa od for 20 days or 4250 UI aXa od for 30 days. Outcomes were the composite of symptomatic and asymptomatic deep vein thrombosis, pulmonary embolism and SVT recurrence or extension in the first 30+/-3 days with a 60+/-3 day follow-up.
  
  
  RESULTS
  98 outcomes (14.7%) were recorded during 93 days among 664 patients (M/F: 246/418, mean age 65). After correction for treatment, outcomes during 33 days were associated with previous venous thromboembolism (VTE) and/or SVT and/or family history of VTE (odds ratio-OR: 2.5; 95% confidence interval - CI: 1.4-4.8; p=0.003). After stopping LMWH treatment, only the absence of varicose veins (OR: 2.5; 95% CI 1.3-5.0; p=0.004) and previous VTE and/or SVT and/or family history of VTE (OR: 1.9; 95% CI:1.0-3.7; p=0.048) were significantly associated with outcomes.
  
  
  CONCLUSIONS
  SVT patients with these factors may deserve a higher intensity and/or longer anticoagulant treatment.
authors.affiliation: Dept. Angiology & Blood Coagulation "Marino Golinelli", S.Orsola-Malpighi University Hospital, Bologna, Italy. Electronic address: benilde.cosmi@unibo.it.
authors.forename: Benilde
authors.initials: B
authors.lastname: Cosmi
authors.affiliation: Dept. Angiology & Blood Coagulation "Marino Golinelli", S.Orsola-Malpighi University Hospital, Bologna, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Filippini
authors.affiliation: Vascular Medicine Unit, Bufalini Hospital, Cesena, Italy.
authors.forename: Fausto
authors.initials: F
authors.lastname: Campana
authors.affiliation: Dept. Angiology, S.Antonio Hospital, Padua, Italy.
authors.forename: Giampiero
authors.initials: G
authors.lastname: Avruscio
authors.affiliation: Angiology Unit - Dept of Internal Medicine, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.
authors.forename: Angelo
authors.initials: A
authors.lastname: Ghirarduzzi
authors.affiliation: Unit of Vascular Medicine and Angiology, Civic Hospital of Faenza, Faenza, Italy.
authors.forename: Eugenio
authors.initials: E
authors.lastname: Bucherini
authors.affiliation: Unit of Angiology, University Hospital of Padua, Padua, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Camporese
authors.affiliation: Dept. of Internal Medicine, G. da Saliceto Hospital, Piacenza, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Imberti
authors.affiliation: Dept. Angiology & Blood Coagulation "Marino Golinelli", S.Orsola-Malpighi University Hospital, Bologna, Italy.
authors.forename: Cristina
authors.initials: C
authors.lastname: Legnani
authors.affiliation: Dept. Angiology & Blood Coagulation "Marino Golinelli", S.Orsola-Malpighi University Hospital, Bologna, Italy.
authors.forename: Gualtiero
authors.initials: G
authors.lastname: Palareti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012008:Recurrence; D012307:Risk Factors; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000209:etiology* / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; C080945:parnaparin
keywords: Deep vein thrombosis; Low molecular weight heparin; Pulmonary embolism; Randomized clinical trial; Superficial vein thrombosis; Venous thromboembolism